DK0880964T3 - Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati - Google Patents

Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati

Info

Publication number
DK0880964T3
DK0880964T3 DK98303447T DK98303447T DK0880964T3 DK 0880964 T3 DK0880964 T3 DK 0880964T3 DK 98303447 T DK98303447 T DK 98303447T DK 98303447 T DK98303447 T DK 98303447T DK 0880964 T3 DK0880964 T3 DK 0880964T3
Authority
DK
Denmark
Prior art keywords
reversal
prevention
aldose reductase
diabetic cardiomyopathy
reductase inhibition
Prior art date
Application number
DK98303447T
Other languages
Danish (da)
English (en)
Inventor
Brian Frank Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0880964T3 publication Critical patent/DK0880964T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98303447T 1997-05-05 1998-05-01 Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati DK0880964T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4582297P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
DK0880964T3 true DK0880964T3 (da) 2004-12-27

Family

ID=21940071

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98303447T DK0880964T3 (da) 1997-05-05 1998-05-01 Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati

Country Status (17)

Country Link
US (1) US5990111A (ja)
EP (1) EP0880964B1 (ja)
JP (1) JP3010153B2 (ja)
KR (1) KR19980086748A (ja)
AT (1) ATE277607T1 (ja)
AU (1) AU725621B2 (ja)
CA (1) CA2236553C (ja)
DE (1) DE69826561T2 (ja)
DK (1) DK0880964T3 (ja)
ES (1) ES2227773T3 (ja)
HU (1) HUP9801022A3 (ja)
IL (1) IL124236A (ja)
MY (1) MY136261A (ja)
NZ (1) NZ330359A (ja)
PT (1) PT880964E (ja)
TW (1) TW589184B (ja)
ZA (1) ZA983720B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
WO2001013786A1 (en) * 1999-08-23 2001-03-01 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US20050239063A1 (en) * 2001-03-30 2005-10-27 Lee Shao C Determination of risk factors for cataract by aldose reductase genotype
US20040047919A1 (en) * 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
EP0322153A3 (en) * 1987-12-21 1990-08-16 Pfizer Inc. Heterocyclic oxophtalazinyl acetic acids
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
US5304557A (en) * 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

Also Published As

Publication number Publication date
MY136261A (en) 2008-09-30
IL124236A (en) 2003-01-12
ES2227773T3 (es) 2005-04-01
DE69826561T2 (de) 2006-03-09
HUP9801022A2 (hu) 2000-03-28
JP3010153B2 (ja) 2000-02-14
DE69826561D1 (de) 2004-11-04
EP0880964A2 (en) 1998-12-02
EP0880964A3 (en) 2002-07-17
TW589184B (en) 2004-06-01
AU6380198A (en) 1998-11-05
ZA983720B (en) 1999-11-04
KR19980086748A (ko) 1998-12-05
PT880964E (pt) 2004-12-31
US5990111A (en) 1999-11-23
JPH10316588A (ja) 1998-12-02
CA2236553A1 (en) 1998-11-05
NZ330359A (en) 2000-06-23
CA2236553C (en) 2002-10-29
ATE277607T1 (de) 2004-10-15
EP0880964B1 (en) 2004-09-29
AU725621B2 (en) 2000-10-19
HUP9801022A3 (en) 2001-10-29

Similar Documents

Publication Publication Date Title
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK2412368T3 (da) Sammensætning til behandling af ar
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DE69802615D1 (de) Triaromatische Verbindungen, diese enthaltende Zusammensetzungen sowie ihre Anwendungen
DK1066056T3 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, ...
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
ATE277607T1 (de) Aldose reductase hemmung zur vorbeugung oder zur umkehrung der diabetischen kardiomyopathie
DK1411917T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bevægelsesforstyrrelser
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
DK1411970T3 (da) Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia
ITMI991605A0 (it) Follatore per il trattamento di cuoio pelli e simili
NO20005548L (no) Mykobakterieinhibitorer
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
DK0896532T3 (da) Acylurinstofforbindelser til behandling af coccidioidomycose i varmblodede dyr
BRPI0511165A (pt) uso de sulglicotìdeo
ITTO981017A0 (it) Dispositivo per la sicurezza personale.
FR2816504B1 (fr) Compositions comprenant au moins une glycosidase, lesdites compositions ne comprenant pas de protease
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
ES1036150Y (es) Elemento de encofrado recuperable para la construccion de columnarios para restos o cenizas.
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.
ES1037450Y (es) Ferula para el tratamiento de uñas incarnadas y restablecimiento de la curvatura de las mismas.